NCT06181227View on ClinicalTrials.gov

A Phase 2 Study of Intravitreal AVD-104 in Diabetic Macular Edema

PHASE2TerminatedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

November 30, 2023

Primary Completion Date

April 5, 2024

Study Completion Date

April 5, 2024

Conditions
Diabetic Macular EdemaDiabetic Retinopathy
Interventions
DRUG

AVD-104

An intravitreal injection of 50 microliters at the doses described will be given. Visual acuity, optical coherence tomography thickness and vascular perfusion will be evaluated for an effect of the drug.

Trial Locations (3)

16507

Erie Retina Research, Erie

75231

Texas Retina Associates, Dallas

76309

West Texas Retina Consultants, Wichita Falls

Sponsors
All Listed Sponsors
lead

Aviceda Therapeutics, Inc.

INDUSTRY